Skip to content

Multimodal Investigation of Intracranial Clot Environment

Multimodal Investigation of Intracranial Clot Environment

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04421326
Acronym
MISO
Enrollment
200
Registered
2020-06-09
Start date
2021-03-14
Completion date
2025-10-31
Last updated
2024-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ichemic Stroke, Brain Ischemia

Keywords

Stroke, Blood Brain Barrier, Ischemia, Thrombus, Interventional Neuroradiology

Brief summary

Analysis of peri clot blood collected at the acute phase of stroke in order to understand physiopathological mechanisms involved in the cerebrovascular damage

Detailed description

It has been shown that immune cells accumulate around the clot at the acute phase of stroke. Leukocytes and their specific chemokines and cytokines regulation may impact cerebrovascular integrity.

Interventions

OTHERAnalysis of the clot

Blood sampling at the site of intracranial occlusion during Mechanical Thrombectomy

Sponsors

Genomic Institute of Montpellier
CollaboratorUNKNOWN
University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

1. Over 18 years of age, 2. Non-dependent for activities of daily living prior to the onset of the MI (Modified Rankin Score \>2) 3. Having an occlusion of a large arterial trunk proven by imaging (angio-MRI or angio-scanner).

Exclusion criteria

1. Patients initially admitted but for whom endovascular treatment will not finally be performed (re-infusion, catheterization failure...) will be excluded from the study. 2. Major patients under guardianship or curatorship or patients deprived of liberty

Design outcomes

Primary

MeasureTime frame
Metalloproteinase 9 quantification60 months
Metalloproteinase 2 quantification60 months

Secondary

MeasureTime frameDescription
Cytokines levels60 monthsProteomic analysis of cytokines IL-1β, TNF-α, IL-6

Countries

France

Contacts

Primary ContactCyril DARGAZANLI, MD MSc
c-dargazanli@chu-montpellier.fr467337532
Backup ContactVincent COSTALAT, MD PhD
v-costalat@chu-montpellier.fr467337532

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026